Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 112

1.

Comprehensive analysis of transcriptome profiles in hepatocellular carcinoma.

Jin Y, Lee WY, Toh ST, Tennakoon C, Toh HC, Chow PK, Chung AY, Chong SS, Ooi LL, Sung WK, Lee CG.

J Transl Med. 2019 Aug 20;17(1):273. doi: 10.1186/s12967-019-2025-x.

2.

Injury patterns associated with personal mobility devices and electric bicycles: an analysis from an acute general hospital in Singapore.

Cha Sow King C, Liu M, Patel S, Goo TT, Lim WW, Toh HC.

Singapore Med J. 2019 Jul 30. doi: 10.11622/smedj.2019084. [Epub ahead of print]

3.

World Cancer Day 2019 - Don't Stop Thinking About Tomorrow.

Farid M, Toh HC.

Ann Acad Med Singapore. 2019 Feb;48(2):42-44. No abstract available.

4.

Loss of BCAA Catabolism during Carcinogenesis Enhances mTORC1 Activity and Promotes Tumor Development and Progression.

Ericksen RE, Lim SL, McDonnell E, Shuen WH, Vadiveloo M, White PJ, Ding Z, Kwok R, Lee P, Radda GK, Toh HC, Hirschey MD, Han W.

Cell Metab. 2019 May 7;29(5):1151-1165.e6. doi: 10.1016/j.cmet.2018.12.020. Epub 2019 Jan 17.

PMID:
30661928
5.

Erratum: The empowerment of all modalities against cancer.

Han S, Toh HC.

Singapore Med J. 2018 Dec;59(12):661. doi: 10.11622/smedj.2018148. No abstract available.

6.

The empowerment of all modalities against cancer.

Han S, Toh HC.

Singapore Med J. 2018 Nov;59(11):560-561. doi: 10.11622/smedj.2018133. No abstract available. Erratum in: Singapore Med J. 2018 Dec;59(12):661.

7.

Cancer Immunotherapy - The Target is Precisely on The Cancer and Also Not.

Koo SL, Wang WW, Toh HC.

Ann Acad Med Singapore. 2018 Sep;47(9):381-387. Review.

8.

Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma.

Lim CJ, Lee YH, Pan L, Lai L, Chua C, Wasser M, Lim TKH, Yeong J, Toh HC, Lee SY, Chan CY, Goh BK, Chung A, Heikenwälder M, Ng IO, Chow P, Albani S, Chew V.

Gut. 2019 May;68(5):916-927. doi: 10.1136/gutjnl-2018-316510. Epub 2018 Jul 3.

9.

Cancer immunotherapy-the end of the beginning.

Toh HC.

Chin Clin Oncol. 2018 Apr;7(2):12. doi: 10.21037/cco.2018.04.03. No abstract available.

10.

Development of a new patient-derived xenograft humanised mouse model to study human-specific tumour microenvironment and immunotherapy.

Zhao Y, Shuen TWH, Toh TB, Chan XY, Liu M, Tan SY, Fan Y, Yang H, Lyer SG, Bonney GK, Loh E, Chang KTE, Tan TC, Zhai W, Chan JKY, Chow EK, Chee CE, Lee GH, Dan YY, Chow PK, Toh HC, Lim SG, Chen Q.

Gut. 2018 Oct;67(10):1845-1854. doi: 10.1136/gutjnl-2017-315201. Epub 2018 Mar 30.

11.

Man with back pain and fever.

Ho AFW, Pek PP, Toh HC.

CJEM. 2018 Mar;20(2):313-314. doi: 10.1017/cem.2017.336. No abstract available.

PMID:
29534779
12.

Awakening immunity against cancer: a 2017 primer for clinicians.

Jain A, Zhang Q, Toh HC.

Chin J Cancer. 2017 Aug 20;36(1):67. doi: 10.1186/s40880-017-0233-4.

13.

GATA4 loss of function in liver cancer impedes precursor to hepatocyte transition.

Enane FO, Shuen WH, Gu X, Quteba E, Przychodzen B, Makishima H, Bodo J, Ng J, Chee CL, Ba R, Seng Koh L, Lim J, Cheong R, Teo M, Hu Z, Ng KP, Maciejewski J, Radivoyevitch T, Chung A, Ooi LL, Tan YM, Cheow PC, Chow P, Chan CY, Lim KH, Yerian L, Hsi E, Toh HC, Saunthararajah Y.

J Clin Invest. 2017 Sep 1;127(9):3527-3542. doi: 10.1172/JCI93488. Epub 2017 Jul 31.

14.

Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized Clinical Trial.

Yap YS, Kwok LL, Syn N, Chay WY, Chia JWK, Tham CK, Wong NS, Lo SK, Dent RA, Tan S, Mok ZY, Koh KX, Toh HC, Koo WH, Loh M, Ng RCH, Choo SP, Soong RCT.

JAMA Oncol. 2017 Nov 1;3(11):1538-1545. doi: 10.1001/jamaoncol.2017.1269.

15.

Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses.

Chew V, Lai L, Pan L, Lim CJ, Li J, Ong R, Chua C, Leong JY, Lim KH, Toh HC, Lee SY, Chan CY, Goh BKP, Chung A, Chow PKH, Albani S.

Proc Natl Acad Sci U S A. 2017 Jul 18;114(29):E5900-E5909. doi: 10.1073/pnas.1706559114. Epub 2017 Jul 3.

16.

Coriolus versicolor (Yunzhi) Use as Therapy in Advanced Hepatocellular Carcinoma Patients with Poor Liver Function or Who Are Unfit for Standard Therapy.

Chay WY, Tham CK, Toh HC, Lim HY, Tan CK, Lim C, Wang WW, Choo SP.

J Altern Complement Med. 2017 Aug;23(8):648-652. doi: 10.1089/acm.2016.0136. Epub 2017 Apr 4.

PMID:
28375640
17.

A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC).

Tai WM, Yong WP, Lim C, Low LS, Tham CK, Koh TS, Ng QS, Wang WW, Wang LZ, Hartono S, Thng CH, Huynh H, Lim KT, Toh HC, Goh BC, Choo SP.

Ann Oncol. 2018 Feb 1;29(2):526. doi: 10.1093/annonc/mdx060. No abstract available.

PMID:
28368515
18.

SEARCH 8Es: A novel point of care ultrasound protocol for patients with chest pain, dyspnea or symptomatic hypotension in the emergency department.

Ahn JH, Jeon J, Toh HC, Noble VE, Kim JS, Kim YS, Do HH, Ha YR.

PLoS One. 2017 Mar 29;12(3):e0174581. doi: 10.1371/journal.pone.0174581. eCollection 2017.

19.

Intraperitoneal immunotherapy with T cells stably and transiently expressing anti-EpCAM CAR in xenograft models of peritoneal carcinomatosis.

Ang WX, Li Z, Chi Z, Du SH, Chen C, Tay JC, Toh HC, Connolly JE, Xu XH, Wang S.

Oncotarget. 2017 Feb 21;8(8):13545-13559. doi: 10.18632/oncotarget.14592.

20.

A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC).

Tai WM, Yong WP, Lim C, Low LS, Tham CK, Koh TS, Ng QS, Wang WW, Wang LZ, Hartano S, Thng CH, Huynh H, Lim KT, Toh HC, Goh BC, Choo SP.

Ann Oncol. 2016 Dec;27(12):2210-2215. doi: 10.1093/annonc/mdw415. Epub 2016 Sep 28. Erratum in: Ann Oncol. 2018 Feb 1;29(2):526.

PMID:
27681866
21.
22.

National Cancer Centre Singapore Consensus Guidelines for Hepatocellular Carcinoma.

Chow PK, Choo SP, Ng DC, Lo RH, Wang ML, Toh HC, Tai DW, Goh BK, Wong JS, Tay KH, Goh AS, Yan SX, Loke KS, Thang SP, Gogna A, Too CW, Irani FG, Leong S, Lim KH, Thng CH.

Liver Cancer. 2016 Apr;5(2):97-106. doi: 10.1159/000367759. Epub 2016 Mar 17.

23.

Local Immune Stimulation by Intravesical Instillation of Baculovirus to Enable Bladder Cancer Therapy.

Ang WX, Zhao Y, Kwang T, Wu C, Chen C, Toh HC, Mahendran R, Esuvaranathan K, Wang S.

Sci Rep. 2016 Jun 8;6:27455. doi: 10.1038/srep27455.

24.

Potential Prognostic Impact of Baseline CEA Level and Surgery of Primary Tumor Among Patients with Synchronous Stage IV Colorectal Cancer: A Large Population Based Study.

Dawood S, Sirohi B, Shrikhande SV, Toh HC, Eng C.

Indian J Surg Oncol. 2015 Sep;6(3):198-206. doi: 10.1007/s13193-015-0419-7. Epub 2015 Jun 7.

25.

Immunotherapy for nasopharyngeal cancer-a review.

Jain A, Chia WK, Toh HC.

Chin Clin Oncol. 2016 Apr;5(2):22. doi: 10.21037/cco.2016.03.08. Review.

26.

Longitudinal metabolic imaging of hepatocellular carcinoma in transgenic mouse models identifies acylcarnitine as a potential biomarker for early detection.

Yaligar J, Teoh WW, Othman R, Verma SK, Phang BH, Lee SS, Wang WW, Toh HC, Gopalan V, Sabapathy K, Velan SS.

Sci Rep. 2016 Feb 2;6:20299. doi: 10.1038/srep20299.

27.

Correction: Methylation Profiles Reveal Distinct Subgroup of Hepatocellular Carcinoma Patients with Poor Prognosis.

Mah WC, Thurnherr T, Chow PK, Chung AY, Ooi LL, Toh HC, Teh BT, Saunthararajah Y, Lee CG.

PLoS One. 2016 Jan 11;11(1):e0146690. doi: 10.1371/journal.pone.0146690. eCollection 2016. No abstract available.

28.

Interaction between tumour-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma.

Garnelo M, Tan A, Her Z, Yeong J, Lim CJ, Chen J, Lim KH, Weber A, Chow P, Chung A, Ooi LL, Toh HC, Heikenwalder M, Ng IO, Nardin A, Chen Q, Abastado JP, Chew V.

Gut. 2017 Feb;66(2):342-351. doi: 10.1136/gutjnl-2015-310814. Epub 2015 Dec 15.

29.

Correction: The Singapore Liver Cancer Recurrence (SLICER) Score for Relapse Prediction in Patients with Surgically Resected Hepatocellular Carcinoma.

Ang SF, Ng ES, Li H, Ong YH, Choo SP, Ngeow J, Toh HC, Lim KH, Yap HY, Tan CK, Ooi LL, Cheow PC, Chung AY, Chow PK, Foo KF, Tan MH.

PLoS One. 2015 May 13;10(5):e0128058. doi: 10.1371/journal.pone.0128058. eCollection 2015. No abstract available.

30.

The Singapore Liver Cancer Recurrence (SLICER) Score for relapse prediction in patients with surgically resected hepatocellular carcinoma.

Ang SF, Ng ES, Li H, Ong YH, Choo SP, Ngeow J, Toh HC, Lim KH, Yap HY, Tan CK, Ooi LL, Cheow PC, Chung AY, Chow PK, Foo KF, Tan MH.

PLoS One. 2015 Apr 1;10(4):e0118658. doi: 10.1371/journal.pone.0118658. eCollection 2015. Erratum in: PLoS One. 2015;10(5):e0128058.

31.

SAG-UPS attenuates proapoptotic SARM and Noxa to confer survival advantage to early hepatocellular carcinoma.

Chang SC, Choo WQ, Toh HC, Ding JL.

Cell Death Discov. 2015 Sep 28;1:15032. doi: 10.1038/cddiscovery.2015.32. eCollection 2015.

32.

Post-operative aspirin use and colorectal cancer-specific survival in patients with stage I-III colorectal cancer.

Goh CH, Leong WQ, Chew MH, Pan YS, Tony LK, Chew L, Tan IB, Toh HC, Tang CL, Fu WP, Chia WK.

Anticancer Res. 2014 Dec;34(12):7407-14. Erratum in: Anticancer Res. 2015 Feb;35(2):1219. Goh, Hin Hock [corrected to Goh, Chin Hock].

PMID:
25503181
33.

Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial.

Cainap C, Qin S, Huang WT, Chung IJ, Pan H, Cheng Y, Kudo M, Kang YK, Chen PJ, Toh HC, Gorbunova V, Eskens FA, Qian J, McKee MD, Ricker JL, Carlson DM, El-Nowiem S.

J Clin Oncol. 2015 Jan 10;33(2):172-9. doi: 10.1200/JCO.2013.54.3298. Epub 2014 Dec 8. Erratum in: J Clin Oncol. 2017 Aug 1;35(22):2590.

34.

Cost-effectiveness of aspirin adjuvant therapy in early stage colorectal cancer in older patients.

Soon SS, Chia WK, Chan ML, Ho GF, Jian X, Deng YH, Tan CS, Sharma A, Segelov E, Mehta S, Ali R, Toh HC, Wee HL.

PLoS One. 2014 Sep 24;9(9):e107866. doi: 10.1371/journal.pone.0107866. eCollection 2014.

35.

Methylation profiles reveal distinct subgroup of hepatocellular carcinoma patients with poor prognosis.

Mah WC, Thurnherr T, Chow PK, Chung AY, Ooi LL, Toh HC, Teh BT, Saunthararajah Y, Lee CG.

PLoS One. 2014 Aug 5;9(8):e104158. doi: 10.1371/journal.pone.0104158. eCollection 2014. Erratum in: PLoS One. 2016;11(1):e0146690.

36.

Novel proteomic biomarker panel for prediction of aggressive metastatic hepatocellular carcinoma relapse in surgically resectable patients.

Tan GS, Lim KH, Tan HT, Khoo ML, Tan SH, Toh HC, Ching Ming Chung M.

J Proteome Res. 2014 Nov 7;13(11):4833-46. doi: 10.1021/pr500229n. Epub 2014 Jun 30.

PMID:
24946162
37.

Induced pluripotent stem cell-derived neural stem cells transduced with baculovirus encoding CD40 ligand for immunogene therapy in mouse models of breast cancer.

Zhu D, Chen C, Purwanti YI, Du S, Lam DH, Wu C, Zeng J, Toh HC, Wang S.

Hum Gene Ther. 2014 Aug;25(8):747-58. doi: 10.1089/hum.2013.160. Epub 2014 Jun 20.

PMID:
24773154
38.

Statins: emerging role in chemoprevention for hepatocellular carcinoma?

Tai WM, Toh HC.

Hepatobiliary Surg Nutr. 2013 Apr;2(2):117-20. doi: 10.3978/j.issn.2304-3881.2012.10.05. No abstract available.

39.

Transposon mutagenesis identifies genes driving hepatocellular carcinoma in a chronic hepatitis B mouse model.

Bard-Chapeau EA, Nguyen AT, Rust AG, Sayadi A, Lee P, Chua BQ, New LS, de Jong J, Ward JM, Chin CK, Chew V, Toh HC, Abastado JP, Benoukraf T, Soong R, Bard FA, Dupuy AJ, Johnson RL, Radda GK, Chan EC, Wessels LF, Adams DJ, Jenkins NA, Copeland NG.

Nat Genet. 2014 Jan;46(1):24-32. doi: 10.1038/ng.2847. Epub 2013 Dec 8.

40.

Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and/or locally recurrent nasopharyngeal carcinoma.

Chia WK, Teo M, Wang WW, Lee B, Ang SF, Tai WM, Chee CL, Ng J, Kan R, Lim WT, Tan SH, Ong WS, Cheung YB, Tan EH, Connolly JE, Gottschalk S, Toh HC.

Mol Ther. 2014 Jan;22(1):132-9. doi: 10.1038/mt.2013.242. Epub 2013 Oct 17.

41.

Zinc finger nuclease-expressing baculoviral vectors mediate targeted genome integration of reprogramming factor genes to facilitate the generation of human induced pluripotent stem cells.

Phang RZ, Tay FC, Goh SL, Lau CH, Zhu H, Tan WK, Liang Q, Chen C, Du S, Li Z, Tay JC, Wu C, Zeng J, Fan W, Toh HC, Wang S.

Stem Cells Transl Med. 2013 Dec;2(12):935-45. doi: 10.5966/sctm.2013-0043. Epub 2013 Oct 28.

42.

MicroRNA-224 targets SMAD family member 4 to promote cell proliferation and negatively influence patient survival.

Wang Y, Ren J, Gao Y, Ma JZ, Toh HC, Chow P, Chung AY, Ooi LL, Lee CG.

PLoS One. 2013 Jul 29;8(7):e68744. doi: 10.1371/journal.pone.0068744. Print 2013.

43.

Identification of serum monocyte chemoattractant protein-1 and prolactin as potential tumor markers in hepatocellular carcinoma.

Wang WW, Ang SF, Kumar R, Heah C, Utama A, Tania NP, Li H, Tan SH, Poo D, Choo SP, Chow WC, Tan CK, Toh HC.

PLoS One. 2013 Jul 18;8(7):e68904. doi: 10.1371/journal.pone.0068904. Print 2013.

44.

Gender, cytidine deaminase, and 5-aza/decitabine--response.

Mahfouz RZ, Koh LS, Teo M, Chee CL, Toh HC, Saunthararajah Y.

Clin Cancer Res. 2013 Jun 1;19(11):3106-7. doi: 10.1158/1078-0432.CCR-13-0872. Epub 2013 May 8. No abstract available.

45.

The evolving landscape of therapeutic drug development for hepatocellular carcinoma.

Chong DQ, Tan IB, Choo SP, Toh HC.

Contemp Clin Trials. 2013 Nov;36(2):605-15. doi: 10.1016/j.cct.2013.03.013. Epub 2013 Apr 13.

PMID:
23591326
46.
47.

Ovarian preservation with subcutaneous transposition in the setting of cytoreductive surgery.

Tan WJ, Jung J, Chia CS, Teo MC, Toh HC, Soo KC.

Int J Surg Case Rep. 2013;4(3):305-7. doi: 10.1016/j.ijscr.2012.12.015. Epub 2013 Jan 17.

48.

Deep sequencing of the hepatitis B virus in hepatocellular carcinoma patients reveals enriched integration events, structural alterations and sequence variations.

Toh ST, Jin Y, Liu L, Wang J, Babrzadeh F, Gharizadeh B, Ronaghi M, Toh HC, Chow PK, Chung AY, Ooi LL, Lee CG.

Carcinogenesis. 2013 Apr;34(4):787-98. doi: 10.1093/carcin/bgs406. Epub 2012 Dec 30.

PMID:
23276797
49.

A Phase 1 dose-finding and pharmacodynamic study of rapamycin in combination with bevacizumab in patients with unresectable hepatocellular carcinoma.

Choo SP, Chowbay B, Ng QS, Thng CH, Lim C, Hartono S, Koh TS, Huynh H, Poon D, Ang MK, Chang S, Toh HC.

Eur J Cancer. 2013 Mar;49(5):999-1008. doi: 10.1016/j.ejca.2012.11.008. Epub 2012 Dec 19.

PMID:
23265712
50.

Toll-like receptor 3 expressing tumor parenchyma and infiltrating natural killer cells in hepatocellular carcinoma patients.

Chew V, Tow C, Huang C, Bard-Chapeau E, Copeland NG, Jenkins NA, Weber A, Lim KH, Toh HC, Heikenwalder M, Ng IO, Nardin A, Abastado JP.

J Natl Cancer Inst. 2012 Dec 5;104(23):1796-807. doi: 10.1093/jnci/djs436. Epub 2012 Nov 29.

Supplemental Content

Support Center